News
Release
Research
Article Cites Viraffinity™ for Dengue Virus (DV) Purification
MONMOUTH
JUNCTION, NJ, July
27, 2016 -- Biotech Support Group reports on a recent research
article describing the simplicity and efficiency of their virus
enrichment technology for viral proteomic analyses from plasma.
The
citation is:
Romain
Fragnoud, Marie Flamand, Frederic Reynier, Philippe Buchy, Vasna
Duong, Alexandre Pachot, Glaucia Paranhos-Baccala and Frederic Bedin.
Differential
proteomic analysis of virus enriched fractions
obtained from plasma pools of patients with dengue fever or severe
dengue.
BMC Infectious Diseases (2015) 15:518.
http://www.ncbi.nlm.nih.gov/pubmed/26572220
In
brief, the article’s authors report a method to compare the
proteomes of virion-enriched fractions purified from plasma pools of
patients with dengue fever or severe dengue. Virions were purified by
ultracentrifugation combined with Viraffinity™.
Following in-gel hydrolysis, peptides were analyzed by LC-MS. The
article states “A technique based on ultracentifugation (Step 1)
followed by concentration using…Viraffinity™,
was created to obtain a fraction of plasma enriched with DV
particles. A positive signal corresponding to monomeric (60 kDa) and
dimeric E protein (120 KDa) was observed in the DV-infected samples,
and became more intense after the Viraffinity™
step…Densitometry indicated that the protein complexity of the
purified samples was reduced by roughly 350-fold compared to the
unpurified samples.”. The authors conclude that the Viraffinity™
based technique of virion-enrichment allowed them to identify two
host proteins that have prognostic value for classifying patients
with acute dengue who are more likely to develop a severe dengue.
“We
are very happy to see that not only is Viraffinity™
useful in LC-MS proteomics, but that it complements the gold-standard
of enrichment using gradient ultracentrifugation. I am very pleased
that the exquisite selectivity profile of Viraffinity™
was in-part the reason these researchers were able to enrich viral
proteomes 350-fold from plasma!” states Swapan Roy, Ph.D.,
President and Founder of Biotech Support Group.
For more information visit: Viraffinity™ at
http://www.biotechsupportgroup.com/Viraffinity-Virus-and-Viral-Component-Isolation-p/v1062.htm
About
Biotech Support Group LLC
Converging
with cultural and technological disruptions forthcoming in
healthcare, Biotech Support Group develops methods for cost effective
and efficient sample prep essential for these expanding markets.
Following a tiered business strategy, the company continues its
growth in the consumable research products area supporting the
rapidly expanding installation of LC-MS instrument and computational
infrastructure. For this market, key products include: AlbuVoid™
and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid
adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal,
and NuGel™ for functional proteomics. From these innovations, the
company has acquired knowledgebase and biomarker intellectual
property assets that support discoveries of protein markers from
blood, with special emphasis on early detection and personalized
medical decisions for cancer patients. For more information, go
to http://www.biotechsupportgroup.com
Contact:
Dr. Swapan Roy & Matthew Kuruc
Biotech Support Group LLC
1 Deer Park Drive, Suite M
Monmouth Junction NJ 08852
732-274-2866 Worldwide
800-935-0628 North America
sales@biotechsupportgroup.com
http://www.biotechsupportgroup.com
